Tuesday, November 15, 2016 11:06:29 AM
1. Too soon. Still in the development, phase which does not effect the balance sheet at this time but gives insight as to how it will in the future. The process of proving the efficacy and safety of the NSS has gone well. The FDA mandate OPC has essentially been met. The process of presenting the surgical process and results to the professional communities in an effort to have them be accepted as the best and standard treatment for acute thoracic spinal cord injury is underway.
2. They don't need to. Their employment packages give them generous amounts of warrants. As the future becomes clearer they may. Again ...too soon.
3. No rate increase in December. Again...too soon. Interest rate increases will be implemented to control economic growth. The Trump agenda has not been delineated sufficiently yet. There will need to be executive and legislative action first and some measured results before the assessment that increasing interest rates are necessary.
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM